{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:15Z","timestamp":1792184655286,"version":"4.4.0"},"reference-count":25,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4261,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Depress. Anxiety"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1002\/da.20014","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T18:01:03Z","timestamp":1086976863000},"page":"241-248","source":"Crossref","is-referenced-by-count":131,"title":["Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study"],"prefix":"10.1155","volume":"19","author":[{"given":"Malcolm","family":"Lader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Stender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"B\u00fcrger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rico","family":"Nil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2004,6,11]]},"reference":[{"key":"10.1002\/da.20014-BIB1|cit3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/15622970209150621","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders","volume":"3","author":"Bandelow","year":"2002","journal-title":"World J Biol Psychiatry"},{"key":"10.1002\/da.20014-BIB2|cit4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0165-0327(97)00182-1","article-title":"Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalised social phobia","volume":"49","author":"Bouwer","year":"1998","journal-title":"J Affect Disord"},{"key":"10.1002\/da.20014-BIB3|cit5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v63n0410","article-title":"Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients","volume":"63","author":"Burke","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.20014-BIB4|cit6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"Recommendations guiding medical physicians in biomedical research involving human subjects","volume":"277","author":"Declaration of Helsinki","year":"1997","journal-title":"J Am Med Assoc"},{"issue":"Suppl","key":"10.1002\/da.20014-BIB5|cit7","first-page":"54","article-title":"Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety","volume":"59","author":"International Consensus Group on Depression and Anxiety","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"Suppl","key":"10.1002\/da.20014-BIB6|cit8","first-page":"S131","article-title":"Escitalopram is efficacious and well tolerated in the treatment of SAD","volume":"5","author":"Kasper","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1002\/da.20014-BIB7|cit9","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","article-title":"Sertraline for social phobia: A double-blind, placebo-controlled crossover study","volume":"152","author":"Katzelnick","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20014-BIB8|cit10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1176\/ajp.155.5.613","article-title":"Social phobia subtypes in the National Comorbidity Survey","volume":"155","author":"Kessler","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20014-BIB9|cit11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-2007-1014302","article-title":"Citalopram in the treatment of social phobia: A report of three cases","volume":"27","author":"Lepola","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/da.20014-BIB10|cit12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004850-200307000-00003","article-title":"Escitalopram (10 to 20 mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"18","author":"Lepola","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.20014-BIB11|cit13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social phobia","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"10.1002\/da.20014-BIB12|cit14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","article-title":"A randomised, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder","volume":"63","author":"Liebowitz","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.20014-BIB13|cit15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archpsyc.1996.01830020077009","article-title":"Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey","volume":"53","author":"Magee","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.20014-BIB14|cit16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-3223(01)01145-3","article-title":"Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine","volume":"50","author":"Owens","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20014-BIB15|cit17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: A placebo-controlled study","volume":"19","author":"Pande","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20014-BIB16|cit18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: A randomised clinical trial","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.20014-BIB17|cit19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","article-title":"Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities","volume":"167","author":"S\u00e1nchez","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1002\/da.20014-BIB18|cit20","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archpsyc.1992.01820040034004","article-title":"Social phobia. Comorbidity and morbidity in an epidemiologic sample","volume":"49","author":"Schneier","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl","key":"10.1002\/da.20014-BIB19|cit21","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.20014-BIB20|cit22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0278-5846(01)00189-0","article-title":"Citalopram for social phobia: A clinical case series","volume":"25","author":"Simon","year":"2001","journal-title":"Prog Neuro-Psychoparmacol Biol Psychiatry"},{"key":"10.1002\/da.20014-BIB21|cit23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00023210-199911040-00006","article-title":"Selective serotonin reuptake inhibitors in the treatment of social phobia: The emerging gold standard","volume":"11","author":"van Ameringen","year":"1999","journal-title":"CNS Drugs"},{"key":"10.1002\/da.20014-BIB22|cit24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","article-title":"Psychopharmacological treatment of social phobia; a double-blind placebo-controlled study with fluvoxamine","volume":"115","author":"van Vliet","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1002\/da.20014-BIB23|cit25","first-page":"91","article-title":"Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the composite International Diagnostic Interview (CIDI)","volume":"2","author":"Wacker","year":"1992","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1002\/da.20014-BIB24|cit26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","article-title":"Escitalopram 10mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"17","author":"Wade","year":"2002a","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.20014-BIB25|cit27","first-page":"256","article-title":"Escitalopram provides continued improvement during long-term treatment of depressed patients in primary care","volume":"6","author":"Wade","year":"2002b","journal-title":"Int J Psychol Clin Pract"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.20014","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/da.20014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:02:50Z","timestamp":1671541370000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.20014"}},"subtitle":["Research Article: Escitalopram in Long-Term Treatment of SAD"],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/da.20014","archive":["Portico"],"relation":{},"ISSN":["1091-4269"],"issn-type":[{"value":"1091-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}